8-K filed Aug 6, 2026 at 07:12 ET
Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven by Recorlev's 81% growth to $56.8M. The GAAP net loss of $31.1M was largely due to a $31M non-cash charge from convertible note exchange agreements, while Adjusted EBITDA improved to $19.3M. The company tightened full-year 2026 revenue guidance to $385-390M, reflecting confidence in continued commercial momentum, and eliminated all remaining 2028 Convertible Notes debt through cash and stock exchanges, strengthening the balance sheet.